Trial Profile
Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Anakinra (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms ATC-Anakinra; ATC-Anakinra1
- 20 Jun 2018 New trial record